At the onset of COVID-19, we began an impact survey to gauge how sponsors and CROs were reacting to the pandemic and how their trials were being affected.
Our findings suggest that a number of trials were put on hold rather than being canceled in an effort to make mid-study changes to enable the trial to continue in a more virtual environment.
We’re also seeing that studies that adopted ePRO prior to COVID-19 have been showing fewer delays than paper-based studies.
“We would be in a very different situation if we did not have ePRO capabilities. We have not experienced any delays in our studies and we’re hearing from some patients that they are even more willing to participate now because ePRO allows them to submit their responses remotely while they are at home more during this time.
ePRO is truly what keeps our research going,” said Sally Urwin, Clinical Data Manager, Hollister Incorporated.
“…we’re hearing from some patients that they are even more willing to participate now because ePRO allows them to submit their responses remotely while they are at home more during this time.”
Patient centricity has proven to increase recruitment, retention, and engagement of patients within a clinical trial. ePRO is a patient-centric tool that empowers patients to report on their own time and from the comfort of their own home. Medrio ePRO is flexible, it allows for patient data collection to be done from anywhere in the world and at any time.
Patient compliance is improved with flexible scheduling based on patient timezones, closeout windows that support time-sensitive data collection, and friendly notifications that integrate with the patient’s lifestyle.
With Medrio, the ease of use is not only for patients. Medrio ePRO has supported over 330 studies across all therapeutic areas and stages of research as the solution is flexible and scalable.
Whether your trial is hybrid or fully remote, BYOD or supplied devices, Medrio ePRO handles all of the complexities of patient data, and we have a team of experts to help you navigate the ever-changing regulatory landscape, survey design, licensing, and more.
“I appreciate Medrio’s commitment to their clients. Their team is responsive to our ePRO needs and they work hard to make system improvements for us. They are continually developing and enhancing an already good system. Also, I really like the ease of configuring my remote studies with their ePRO system.
With Medrio, setting up ePRO forms is just like setting up EDC forms/eCRFs and I can do it all myself. In general, Medrio configuration is easy to learn, and once learned, a data manager is ready to set up their own ePRO studies, quickly and easily,” explained Sally Urwin.
If you’re considering switching from paper to ePRO, the ePRO consortium recently issued risk assessment and mitigation strategies with regards to COVID-19.
The assessment outlines guidance from the regulatory bodies, and details strategies to continue to facilitate the collection of PRO data in clinical trials.